07 November 2023
07 November 2023
The FDA guidance to provide clarity for sponsors running trials during war, disaster and PHE is released but questions remain.
The company submitted a supplemental new drug application to the FDA in June to complete the approval for Nefecon.
The domvanalimab regimen showed an encouraging overall response rate and progression-free survival.
Bayer’s Kerendia is the first nonsteroidal mineralocorticoid receptor antagonist for diabetes-related chronic kidney disease.
TILT Biotherapeutics’s candidate demonstrated a good safety profile and promising anti-tumour activity.
The data showed that 64% of the subjects who received Annamycin had stable disease through two cycles.
A 77% disease control rate was observed in trial subjects, as well as a partial response and stable disease rate of 38.5%.
The dose-ranging Phase IIa trial will evaluate the efficacy and safety of RTP-026.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
